Singapore’s Restalyst develops new method to improve liver cancer diagnosis

SINGAPORE, Nov. 9, 2017 /PRNewswire/ — Singapore biomedical firm Restalyst has developed a new algorithm to detect liver cancer more accurately, improving the sensitivity to 90%. The new methodology looks at three factors: membrane bound protein ERBB3 …
( read original story …)


Related Post